Clinical Trials Directory

Trials / Terminated

TerminatedNCT01819675

Effect of Repetitive Transcranial Magnetic Stimulation (rTMS) Over the Brain on the Neurotransmitter Binding

Effect of rTMS Over Primary Motor Cortex on Gamma-aminobutyric Acid A (GABAA)-[18F]Flumazenil Binding: A Positron Emission Tomography (PET) Study

Status
Terminated
Phase
N/A
Study type
Interventional
Enrollment
6 (actual)
Sponsor
Seoul National University Bundang Hospital · Academic / Other
Sex
All
Age
18 Years – 50 Years
Healthy volunteers
Accepted

Summary

The purpose of this study is to determine whether repetitive transcranial magnetic stimulation (rTMS) over the brain can modulate the binding of neurotransmitter (GABA in this study) to its receptor using the special PET study.

Detailed description

Repetitive transcranial magnetic stimulation (rTMS) can modulate the excitability of cortex but exact mechanism is not well determined in human-beings. Changes in some neurotransmitters' status in brain after rTMS have been suggested as a possible mechanism, but role of GABA is not clear. Twelve healthy people will be recruited. They will receive the rTMS over the primary motor cortex of the dominant hand. Individual subject will receive three sessions of rTMS with wash-out period (more than 3 days) between the rTMS sessions. Three rTMS sessions are high frequency (10Hz), low frequency (1Hz) and sham rTMS. The order of rTMS sessions will be randomly decided. After completing each rTMS session, \[18F\]flumazenil-PET will be checked. The purpose of this study is to investigate 1)whether rTMS over the primary motor cortex can modulate the \[18F\]flumazenil binding potential and 2)whether the modulation of \[18F\]flumazenil binding potential by rTMS can be different according to the applied frequency of rTMS.

Conditions

Interventions

TypeNameDescription
DEVICELow frequency rTMS
DEVICEHigh frequency rTMS
DEVICESham rTMS

Timeline

Start date
2013-03-01
Primary completion
2016-02-01
Completion
2016-02-01
First posted
2013-03-27
Last updated
2017-06-27

Locations

1 site across 1 country: South Korea

Source: ClinicalTrials.gov record NCT01819675. Inclusion in this directory is not an endorsement.